In:
Frontiers in Immunology, Frontiers Media SA, Vol. 12 ( 2021-12-16)
Abstract:
Cellular immunotherapy represented by CD19-directed chimeric antigen receptor T (CAR-T) cells has achieved great success in recent years. An increasing number of CAR-T therapies are being developed for cancer treatment, but the frequent and varied adverse events, such as “on-target, off-tumor toxicity”, limit CAR-T application. Here, we identify the target antigen expression patterns of CAR therapies in 18 tissues and organs (peripheral blood mononuclear cells, bone marrow, lymph nodes, spleen, heart, ascending aortic tissue, trachea, lung, skin, kidney, bladder, esophagus, stomach, small intestine, rectum, liver, common bile duct, and pancreas) from healthy human samples. The atlas determines target antigens expressed on some normal cell types, which facilitates elucidating the cause of “on-target, off-tumor toxicity” in special tissues and organs by targeting some antigens, but not others. Moreover, we describe the target antigen expression patterns of B-lineage-derived malignant cells, acute myeloid leukemia (AML), and solid tumors. Overall, the present study indicates the pathogenesis of “on-target, off-tumor toxicity” during CAR therapies and provides guidance on taking preventive measures during CAR treatment.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2021.799206
DOI:
10.3389/fimmu.2021.799206.s001
DOI:
10.3389/fimmu.2021.799206.s002
DOI:
10.3389/fimmu.2021.799206.s003
DOI:
10.3389/fimmu.2021.799206.s004
DOI:
10.3389/fimmu.2021.799206.s005
DOI:
10.3389/fimmu.2021.799206.s006
DOI:
10.3389/fimmu.2021.799206.s007
DOI:
10.3389/fimmu.2021.799206.s008
DOI:
10.3389/fimmu.2021.799206.s009
DOI:
10.3389/fimmu.2021.799206.s010
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2021
detail.hit.zdb_id:
2606827-8
Permalink